Amgen (AMGN) Announces Full Results from Part 1 of the Phase 2 study of MariTide

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), which is a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, MariTide exhibited up to ~20% average weight loss in people who are living with obesity without Type 2 diabetes (T2D) as compared with 2.6% in the placebo arm, and up to ~17% average weight loss in people who are living with obesity with T2D in comparison to 1.4% in the placebo arm, per the efficacy estimand.

Amgen (AMGN) Announces Full Results from Part 1 of the Phase 2 study of MariTide

A pharmacist filling a prescription for a complex drug developed by the company.

Amgen Inc. also added that weight loss had not plateaued by 52 weeks, which indicates the potential for further weight reduction. Apart from the meaningful weight loss, MariTide showcased a robust and sustained reduction in hemoglobin A1c (HbA1c) of up to 2.2% in people who have obesity and T2D. MariTide’s monthly or less frequent dosing can improve adherence and long-term weight control. This provides an opportunity to optimize health outcomes for people who have obesity, Type 2 diabetes, and related conditions, highlighted Amgen Inc..

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.